News »Agilvax To Attend Biotech Showcase™ 2015


Albuquerque, NM

January 5, 2015

About Agilvax

Agilvax Inc. develops targeted vaccine therapies for infectious diseases and cancer utilizing its proprietary virus-like particle (VLP) platform technology. The company has a pipeline and platform that is based on VLPs derived from RNA bacteriophage that have been engineered to incorporate novel vaccine components. This platform allows the company to rapidly identify ideal VLP candidates to create novel and effective vaccine therapies. This novel VLP platform facilitates both vaccine discovery and implementation through a unique affinity selection process (reverse vaccinology). The Company was founded in 2011 and has headquarters in Albuquerque, NM, USA.

Safe Harbor Statement

The anticipated presentation will contain “forward-looking statements” for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the adequacy of the Company’s capital to fund its ongoing operations, the potential for VLPs to treat or prevent any disease, potential VLP side effect profiles, the Company and its collaborators’ abilities to successfully complete clinical trials, timing and eventual prospects for completion of clinical trials and any approval to market any of the Company’s products and the prospects for the Company’s collaborations. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company’s financial resources and whether they will be sufficient to meet the Company’s business objectives and operational requirements; results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by the Company’s intellectual property; risks related to the therapeutic discovery and the regulatory approval process; and, the impact of competitive products and technological changes. The Company’s forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Agilvax Contacts

Federica Pericle, Ph.D., M.B.A.
President and Chief Executive Officer
T: 505-200-9541
fpericle@agilvax.com

Michael Perrine, M.S., M.B.A.
Director of Business Development
T: 505-200-9541
mperrine@agilvax.com


Back to News